Nasal Polyps Treatment Market Report 2026

Nasal Polyps Treatment Market Overview

• Nasal Polyps Treatment market size has reached to $5.68 billion in 2025 • Expected to grow to $8.9 billion in 2030 at a compound annual growth rate (CAGR) of 9.4% • Growth Driver: Rising Healthcare Expenditure Drives The Nasal Polyps Treatment Market • Market Trend: Rise In Fda Approval In Nasal Polyps Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Nasal Polyps Treatment Market?

Nasal polyps are soft, painless, noncancerous growths on the lining of your nasal passages or sinuses. They dangle like grapes or teardrops and are linked with asthma, persistent infections, allergies, medication sensitivity, and other immunological disorders. The nasal polyps treatment market consists of sales of nasal polyps treatment by entities (organizations, sole traders, and partnerships) that are used for the treatment of nasal polyps which shrink or disrepair the nasal polyps. Nasal polyps are soft, painless noncancerous growths on the lining of your nasal passages or sinuses. They dangle like grapes or teardrops and are linked with asthma, persistent infection, allergies, medication sensitivity, and other immunological disorders.

What Is The Nasal Polyps Treatment Market Growth Forecast?

The nasal polyps treatment market size is expected to see strong growth in the next few years. It will grow to $8.9 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to rising demand for targeted biologic drugs, increased r&d in nasal therapeutics, expansion of outpatient minimally invasive procedures, growing awareness of nasal polyp management, launch of innovative anti-inflammatory formulations. Major trends in the forecast period include increasing adoption of biologic therapies for chronic nasal polyps, growing demand for minimally invasive sinus procedures, rising use of combination therapy for persistent cases, expanding preference for nasal corticosteroid sprays, increasing clinical trials for novel anti-inflammatory drugs.

What Is The Driver Of The Nasal Polyps Treatment Market?

Rising healthcare expenditure is expected to drive the nasal polyps treatment market. Healthcare expenditure refers to the total monetary resources spent by individuals, governments, and organizations within a given healthcare system to cover the costs of medical services, treatments, medications, and healthcare infrastructure. As healthcare budgets expand, there will likely be greater resources allocated to the diagnosis, management, and treatment of nasal polyps. This financial commitment can lead to improved patient access to advanced therapies, innovative treatment options, and enhanced research and development, ultimately fueling the market’s growth. For instance, in April 2025, according to the Office for National Statistics, a UK-based statistics authority, the UK government’s net research and development expenditure increased to £17.4 billion (~US$21.8 billion) in 2023 from £16.1 billion (~US$20.1 billion) in 2022, reflecting an 8.2% rise. Therefore, rising healthcare expenditure is driving the nasal polyps treatment industry.

Key Players In The Global Nasal Polyps Treatment Market

Major companies operating in the nasal polyps treatment market are Sanofi SA, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Genentech Inc., Glenmark Pharmaceuticals Ltd., Lupin Limited, Novartis AG, Optinose US Inc., Pfizer Inc., Regeneron Pharmaceuticals Inc., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Zydus Cadila Ltd., Amgen Inc., Takeda Pharmaceutical Company Ltd., Eli Lilly and Company, Daiichi Sankyo Company Ltd., Shionogi Co Ltd, Astellas Pharma Inc., Allakos Inc, Lyra Therapeutics Inc.

Global Nasal Polyps Treatment Market Trends and Insights

Major companies operating in the Nasal Polyps Treatment market are seeking Food and Drug Administration (FDA) approvals to launch new treatments. Food and Drug Administration (FDA) approvals are the regulatory processes by which the U.S. FDA evaluates and authorizes the marketing and distribution of drugs, medical devices, and food products, ensuring their safety and efficacy for public use. For instance, in September 2024, Regeneron Pharmaceuticals, Inc., a US-based biopharmaceutical company and Sanofi SA France-based pharmaceutical and healthcare company, announced approval of Dupixent (dupilumab) as an add-on maintenance treatment for adolescent patients aged 12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) by the U.S. Food and Drug Administration (FDA). This approval marks it as the first and only biologic treatment specifically indicated for this age group. This approval addresses the unmet medical needs of approximately 9,000 U.S. adolescents suffering from CRSwNP, offering a new option that improves symptoms, reduces nasal polyp recurrence, and enhances overall quality of life.

What Are Latest Mergers And Acquisitions In The Nasal Polyps Treatment Market?

In May 2025, Paratek Pharmaceuticals, a US-based provider of specialty therapies, acquired Optinose, Inc., for approximately $330 million. With this acquisition, Paratek aims to diversify its commercial offering beyond its flagship antibiotic and leverage its sales infrastructure to expand XHANCE adoption among both primary care and specialist providers. Optinose is a U.S.-based biopharmaceutical company that develops drug-device combination nasal therapies, including XHANCE (fluticasone propionate with a proprietary Exhalation Delivery System) for chronic rhinosinusitis.

What Defines the Nasal Polyps Treatment Market?

The nasal polyps treatment market includes revenues earned by entities by nasal corticosteroids, oral and injectable corticosteroids, and other medications. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Nasal Polyps Treatment Market Report 2026?

The nasal polyps treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the nasal polyps treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.